Home › Companies › Keros Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Keros Therapeutics, Inc.’s Form 8-K, filed 2026-06-03 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Explore Keros Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Keros Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-03 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Jean-Jacques Bienaimé | 10,093,559 | -- | -- | 5,156,153 | 2,243,514 | Majority: yes |
| Elect Director: Charles Newton | 14,716,598 | -- | -- | 533,114 | 2,243,514 | Majority: yes |
| Proposal 2: Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026 The Company's stockholders appr | 16,708,279 | 783,953 | 994 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3 | 14,273,625 | 974,049 | 2,038 | -- | 2,243,514 | Majority: yes |
Source: Keros Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-03 — read the filing on EDGAR.
Each item below shows how the 180 asset managers that disclosed a Keros Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Keros Therapeutics, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3”): 14,273,625 for, 974,049 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 19,791,837 outstanding shares: 72% for, 5% against (77% of the company cast a for/against vote).
The 178 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BlackRock | 2,039,611 | 0 | 0 | 0 | For |
| Vanguard | 1,620,084 | 1 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 1,326,947 | 0 | 0 | 0 | For |
| Federated Hermes | 1,194,916 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 759,155 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 672,760 | 0 | 0 | 0 | For |
| Fidelity | 646,450 | 0 | 0 | 0 | For |
| State Street | 507,857 | 0 | 0 | 0 | For |
| Madison Avenue Partners, LP | 0 | 452,277 | 0 | 0 | Against |
| DE Shaw | 439,050 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 403,443 | 0 | 0 | 0 | For |
| Charles Schwab | 360,015 | 0 | 0 | 0 | For |
| Two Sigma | 326,214 | 0 | 0 | 0 | For |
| BESSEMER INVESTMENT MANAGEMENT LLC | 287,706 | 0 | 0 | 0 | For |
| AQR | 272,088 | 0 | 0 | 0 | For |
| Nuveen | 262,332 | 0 | 0 | 0 | For |
| TIAA | 260,385 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 244,638 | 0 | 0 | 0 | For |
| SEI | 183,158 | 0 | 0 | 0 | For |
| Dimensional | 171,917 | 0 | 0 | 0 | For |
| Citadel | 167,546 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 162,294 | 0 | 0 | 0 | For |
| MACKENZIE FINANCIAL CORP | 152,450 | 0 | 0 | 0 | For |
| Invesco | 148,507 | 0 | 0 | 0 | For |
| EA Series Trust | 145,517 | 0 | 0 | 0 | For |
Showing the 25 largest of 178 asset managers. See all 178 in the interactive database.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Keros Therapeutics, Inc.’s own tally for this item (“Elect Director: Charles Newton”): 14,716,598 for, 533,114 withheld, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 19,791,837 outstanding shares: 74% for, 3% withheld (77% of the company cast a for/withheld vote).
The 59 asset managers below cast 100% of the shares they voted on this item FOR (5,779,670 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,475,943 | 0 | 1 | 0 | For |
| BlackRock | 1,116,062 | 0 | 0 | 0 | For |
| Fidelity | 614,783 | 0 | 0 | 0 | For |
| Federated Hermes | 514,400 | 0 | 0 | 0 | For |
| TIAA | 260,385 | 0 | 0 | 0 | For |
| Charles Schwab | 179,991 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 162,294 | 0 | 0 | 0 | For |
| EA Series Trust | 145,517 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 143,853 | 0 | 0 | 0 | For |
| Dimensional | 123,808 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 98,754 | 0 | 0 | 0 | For |
| Nationwide | 90,975 | 0 | 0 | 0 | For |
| SEI | 73,492 | 0 | 0 | 0 | For |
| American Century | 66,359 | 0 | 0 | 0 | For |
| Equitable | 62,765 | 0 | 0 | 0 | For |
| Invesco | 61,793 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 58,899 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 49,500 | 0 | 0 | 0 | For |
| GuideStone | 49,297 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 47,584 | 0 | 0 | 0 | For |
| Goldman Sachs | 42,218 | 0 | 0 | 0 | For |
| MFS | 40,860 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 35,747 | 0 | 0 | 0 | For |
| AQR | 34,582 | 0 | 0 | 0 | For |
| WisdomTree | 31,176 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 7 wordings of this item as funds reported it.
66% Majority: yes · of votes cast
Keros Therapeutics, Inc.’s own tally for this item (“Elect Director: Jean-Jacques Bienaimé”): 10,093,559 for, 5,156,153 withheld, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 19,791,837 outstanding shares: 51.0% for, 26% withheld (77% of the company cast a for/withheld vote).
The 59 asset managers below cast 100% of the shares they voted on this item FOR (4,630,028 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,475,234 | 0 | 710 | 0 | For |
| BlackRock | 1,116,062 | 0 | 0 | 0 | For |
| Fidelity | 614,783 | 0 | 0 | 0 | For |
| Federated Hermes | 514,400 | 0 | 0 | 0 | For |
| TIAA | 260,385 | 0 | 0 | 0 | For |
| Charles Schwab | 179,991 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 162,294 | 0 | 0 | 0 | For |
| EA Series Trust | 0 | 0 | 145,517 | 0 | Abstain |
| OLD WESTBURY FUNDS INC | 0 | 0 | 143,853 | 0 | Abstain |
| Dimensional | 0 | 0 | 123,808 | 0 | Abstain |
| Columbia Threadneedle | 98,754 | 0 | 0 | 0 | For |
| Nationwide | 9,748 | 0 | 81,227 | 0 | Abstain |
| SEI | 0 | 0 | 73,492 | 0 | Abstain |
| American Century | 0 | 0 | 66,359 | 0 | Abstain |
| Equitable | 43,165 | 0 | 19,600 | 0 | For |
| Invesco | 61,793 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 58,899 | 0 | Abstain |
| BRIDGEWAY FUNDS INC | 0 | 0 | 49,500 | 0 | Abstain |
| GuideStone | 0 | 0 | 49,297 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 47,584 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 42,218 | 0 | Abstain |
| MFS | 0 | 0 | 40,860 | 0 | Abstain |
| SEI Exchange Traded Funds | 0 | 0 | 35,747 | 0 | Abstain |
| AQR | 0 | 0 | 34,582 | 0 | Abstain |
| WisdomTree | 0 | 0 | 31,176 | 0 | Abstain |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
96% Majority: yes · of votes cast
Keros Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December ”): 16,708,279 for, 783,953 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 19,791,837 outstanding shares: 84% for, 4% against (88% of the company cast a for/against vote).
The 59 asset managers below cast 99.9% of the shares they voted on this item FOR (5,794,400 for, 1 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,475,943 | 1 | 0 | 0 | For |
| BlackRock | 1,116,062 | 0 | 0 | 0 | For |
| Fidelity | 614,783 | 0 | 0 | 0 | For |
| Federated Hermes | 514,400 | 0 | 0 | 0 | For |
| TIAA | 260,385 | 0 | 0 | 0 | For |
| Charles Schwab | 179,991 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 162,294 | 0 | 0 | 0 | For |
| EA Series Trust | 145,517 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 143,853 | 0 | 0 | 0 | For |
| Dimensional | 123,808 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 98,754 | 0 | 0 | 0 | For |
| Nationwide | 90,975 | 0 | 0 | 0 | For |
| SEI | 73,492 | 0 | 0 | 0 | For |
| American Century | 66,359 | 0 | 0 | 0 | For |
| Equitable | 62,765 | 0 | 0 | 0 | For |
| Invesco | 61,793 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 58,899 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 49,500 | 0 | 0 | 0 | For |
| GuideStone | 49,297 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 47,584 | 0 | 0 | 0 | For |
| Goldman Sachs | 42,218 | 0 | 0 | 0 | For |
| MFS | 40,860 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 35,747 | 0 | 0 | 0 | For |
| AQR | 34,582 | 0 | 0 | 0 | For |
| WisdomTree | 31,176 | 0 | 0 | 0 | For |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Ranked by the number of Keros Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 19,791,837 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BlackRock | 10.31% |
| 2 | Vanguard | 8.19% |
| 3 | Nantahala Capital Management, LLC | 6.70% |
| 4 | Federated Hermes | 6.04% |
| 5 | ORBIMED ADVISORS LLC | 3.84% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 3.40% |
| 7 | Fidelity | 3.27% |
| 8 | State Street | 2.57% |
| 9 | Madison Avenue Partners, LP | 2.29% |
| 10 | DE Shaw | 2.22% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 12.19% | 13F |
| Jasbir Seehra, Ph.D. | 9.46% | DEF14A |
| Vanguard Group | 7.71% | 13F |
| Nantahala Capital Management, LLC | 6.87% | 13G |
| Madison Avenue International LP | 4.16% | 13G |
| Geode Capital | 3.44% | 13F |
| State Street | 2.84% | 13F |
| Citadel Advisors | 2.80% | 13F |
| D.E. Shaw | 2.57% | 13F |
| Renaissance Technologies | 2.29% | 13F |
Percentages above are of 19,791,837 shares outstanding, as reported by Keros Therapeutics, Inc. on its Form 10-Q dated 2026-05-08 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Keros Therapeutics, Inc.’s 10-Q dated 2026-05-08. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Keros Therapeutics, Inc.'s shareholder meeting held 2026-06-03, in the 2025-2026 proxy season, 180 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 841 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Keros Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-03.
Keros Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).